Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Health, Inc. (HIMS) shares have significantly outperformed, returning +24.4% over the past month against the S&P 500's +2.7%. The company projects robust growth, with current quarter EPS expected to rise 50% year-over-year to $0.09 and current fiscal year revenue estimated at $2.35 billion, a 58.9% increase. Despite these growth prospects, recent reported results showed slight misses on consensus estimates, and HIMS holds a Zacks Rank #3 (Hold) and a 'D' Value Style Score, indicating it trades at a premium to peers and is expected to perform in line with the broader market.

Analysis

Hims & Hers Health, Inc. has demonstrated significant recent stock momentum, with a +24.4% return over the past month that vastly outpaces the S&P 500's +2.7% gain. This performance is underpinned by strong forward-looking estimates, including a projected 50% year-over-year EPS increase for the current quarter and a 122.2% rise for the current fiscal year. Revenue forecasts are similarly robust, with an expected 58.9% YoY increase for the current fiscal year, though this is projected to decelerate to 19% in the next fiscal year. However, these bullish growth metrics are tempered by several cautionary factors. Analyst consensus estimates for earnings have remained unchanged over the past 30 days, indicating a lack of new upward revisions. Furthermore, the company's most recent quarter showed a miss on both revenue (-1.51%) and EPS (-5.56%) consensus estimates, and it has only surpassed EPS estimates once in the last four quarters. This execution risk is coupled with a high valuation, as indicated by a Zacks Value Style Score of 'D', suggesting the stock trades at a premium. The resulting Zacks Rank #3 (Hold) implies an expectation of near-term performance in line with the broader market, reflecting a balance between high growth prospects and concerns over valuation and consistent execution.

Key Decisions for Investors

• Given the stock's significant +24.4% run-up in the past month and its premium valuation, investors should be cautious about initiating new long positions at current price levels.
• Monitor the company's upcoming earnings reports closely for its ability to meet or exceed consensus, as its history of missing EPS estimates presents a key execution risk to the growth narrative.
• While the forward-looking growth is compelling, the stagnant analyst estimates and 'Hold' rating suggest much of this optimism may already be priced in, warranting a hold-and-watch approach rather than an aggressive buy until execution improves.